AlphAIAlphAI — Financial news for AI agents
benzinga.comAUG 242 min read$DRI

This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday - Darden Restaurants (NYSE:DRI), Ja

Analysts upgraded four companies: Baird raised Darden (DRI) to Outperform with a $250 target, Wolfe upgraded Janux (JANX) to Outperform with a $23 target, UBS upgraded Celestica (CLS) to Buy with a $430 target, and Wolfe upgraded PulteGroup (PHM) to Outperform with a $129 target. All companies closed at or near their respective targets on Friday.

Original reporting
benzinga.com
Published Aug 24, 2026, 3:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 5:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$DRI
Bullish
medium confidence
Mentioned
$DRI · $JANX · $CLS · $PHM
Relevance
7/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$DRIBullishMed
01

Why it matters

Upgrades provide fresh bullish signals for the four companies, potentially influencing short-term trading decisions.

02

Market read

Four U.S. stocks received analyst upgrades, offering modest trading opportunities.

03

What to watch

Potential earnings miss or sector headwinds could negate upgrade impact.

Relevance 7/10Novelty 6/10Timing: Monday

Background

Analyst rating changes were released after market close, highlighting new target prices and outlooks.

Company-level read

Ticker impact

$DRIBullishMedium confidence
Context

Baird upgraded Darden Restaurants to Outperform with a $250 price target.

Expected impact

Likely modest price increase.

Evidence & confidence

Upgrade signals improved outlook; target above current price.

$JANXBullishMedium confidence
Context

Wolfe Research upgraded Janux Therapeutics to Outperform with a $23 price target.

Expected impact

Potential short-term rally.

Evidence & confidence

Upgrade and higher target could attract buyers.

$CLSBullishMedium confidence
Context

UBS upgraded Celestica to Buy with a $430 price target.

Expected impact

Possible price uptick.

Evidence & confidence

Buy rating and higher target suggest stronger outlook.

$PHMNeutralLow confidence
Context

Wolfe Research upgraded PulteGroup to Outperform with a $129 price target.

Expected impact

Limited immediate move.

Evidence & confidence

Target matches current price; impact may be muted.

Market effects

Sector

Analyst upgrades may lift broader restaurant, biotech, electronics, and homebuilding sectors.

Regional

U.S. equity markets could see modest gains in related sectors.

Global

Limited to U.S. listed companies; minimal global effect.

Counterpoint

What could challenge this read

Upgrades may be premature if underlying fundamentals are weak.

Key entities

  • Research Firm
    Baird

    Issued upgrade for Darden Restaurants.

  • Research Firm
    Wolfe Research

    Issued upgrades for Janux Therapeutics and PulteGroup.

  • Research Firm
    UBS

    Issued upgrade for Celestica.

Read at source← All news

Related articles

SEP 14
$IBPMed

Home Builders Stocks Q2 Earnings: Installed Building Products (NYSE:IBP) Best of the Bunch

Installed Building Products (NYSE:IBP) led Q2 earnings among home builders, while NVR (NYSE:NVR) reported the weakest results with revenue down 10.5% YoY. D.R. Horton (NYSE:DHI) met revenue expectations but missed full-year guidance. PulteGroup (NYSE:PHM) beat revenue and EPS estimates despite a 9.6% YoY decline. NVR, DHI, and PHM stocks are down 3%, 4.7%, and 4.8% since reporting, respectively.

yahoo.com3 min
SEP 14
$JANXLow

Janux Therapeutics Doses First Patient In Phase 1 Study Of JANX013

Janux Therapeutics (JANX) dosed the first patient in a Phase 1 trial for JANX013, a treatment for metastatic castration-resistant prostate cancer (mCRPC), in combination with JANX007. The study will evaluate safety, tolerability, and preliminary efficacy. JANX013 aims to enhance anti-tumor immune responses. JANX stock is up 1.81% at $17.41.

rttnews.com2 min